Halozyme Therapeutics (HALO) Tops Q4 EPS by 18c; Guides FY23
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $68.99 +0.64%
Revenue Growth %: +23.1%
Financial Fact:
Revenues under collaborative agreements: 5.49M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Revenue Growth %: +23.1%
Financial Fact:
Revenues under collaborative agreements: 5.49M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q4 EPS of $0.48, $0.18 better than the analyst estimate of $0.30. Revenue for the quarter came in at $181 million versus the consensus estimate of $192.05 million.
GUIDANCE:
Halozyme Therapeutics sees FY2023 revenue of $815-845 million, versus the consensus of $868.12 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Sun Communities names Ileana McAlary as general counsel and EVP
- AXT appoints Tracy Liu to its board of directors
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
